Methylene blue is an FDA-approved prescription treatment for acquired methemoglobinemia. Cognitive and mitochondrial claims discussed online fall outside that approval and rely largely on preclinical or limited human evidence. Chemical-grade products are not equivalent to pharmaceutical formulations.
Small molecule
Methylene Blue
Methylene blue is an FDA-approved prescription treatment for acquired methemoglobinemia. Cognitive and mitochondrial claims discussed online fall outside that approval and rely largely on preclinical or limited human evidence. Chemical-grade products are not equivalent to pharmaceutical formulations.
Regulatory watch
Last reviewed Jul 1, 2026
Next review Jul 29, 2026
Evidence snapshot
Methylene blue is FDA-approved for the treatment of methemoglobinemia, available as prescription-only Provayblue and Proveblue (FDA NDA 020226).
Preclinical research has explored methylene blue's effects on mitochondrial respiration, with studies suggesting it may enhance mitochondrial function and provide neuroprotection in animal models (Biochem Pharmacol, 2014).
A study on chronic cerebral hypoperfusion found therapeutic benefits of methylene blue on cognitive impairment in animal models (J Alzheimers Dis, 2014).
Non-pharmaceutical-grade methylene blue products sold online may contain impurities including heavy metals. The FDA-approved injectable formulation is manufactured to pharmaceutical standards, unlike chemical-grade or research-grade products marketed to biohackers.
Research record
What the evidence record says
- Evidence grade
- Not Graded
- Regulatory status
- Methylene Blue regulatory status has not been fully reviewed by Peptide Report editorial team. See company profiles and regulatory watch for current status.
Evidence records
Studies, registries, reviews, and regulatory records
Evidence review pending
- Detailed evidence review for Methylene Blue is pending editorial assessment. Current summary reflects available public records.
Records: Provayblue (methylene blue) FDA Label - NDA 020226, Mitochondrial respiration as a target for neuroprotection and cognitive enhancement, Therapeutic benefits of methylene blue on cognitive impairment during chronic cerebral hypoperfusion
Evidence timeline
What changed, and when
Peptide Report last reviewed Methylene Blue on 2026-07-01.
Direct answers
Frequently asked questions
What is Methylene Blue?
Methylene Blue is a small molecule tracked by Peptide Report. See the full profile for current editorial assessment.
Open research questions
What is still unknown
- What is the complete human evidence base for Methylene Blue?
- What are the long-term safety considerations for Methylene Blue?
Tracked claims
Methylene blue is FDA-approved for methemoglobinemia treatment.
Evidence level: Primary regulatory
Sources: Provayblue (methylene blue) FDA Label - NDA 020226, Methylene blue - Wikipedia
How to read this: Confirm approval status against FDA labeling. This is the only FDA-approved indication. All other uses are off-label.
Methylene blue may enhance mitochondrial function and cognitive performance at low doses.
Evidence level: Preclinical
Sources: Mitochondrial respiration as a target for neuroprotection and cognitive enhancement, Therapeutic benefits of methylene blue on cognitive impairment during chronic cerebral hypoperfusion
How to read this: Supported by preclinical/animal studies only. No FDA-approved indication for cognitive enhancement or mitochondrial therapy. Human clinical trials for these uses are limited. Do not present as established therapy.
Non-pharmaceutical methylene blue products sold online raise quality and purity concerns.
Evidence level: Regulatory observation
Sources: Provayblue (methylene blue) FDA Label - NDA 020226, Methylene blue - Wikipedia
How to read this: Chemical-grade and research-grade methylene blue are not manufactured to pharmaceutical standards. Track quality concerns without directing users to specific sources.
Free report
Get the source-quality checklist
Use the same checklist Peptide Report uses to separate Methylene Blue claims, source records, supplier documentation, and media signals.
V1 collects email, role, and topic interest only. No medication, health-condition, dosing, or current-use data is collected in this form.
Formspree processes this submission for Peptide Report. Privacy notice.
Sources on this page
Each source record is linked to the claim or evidence note it supports.
Provayblue (methylene blue) FDA Label - NDA 020226
Provayblue (methylene blue) FDA Label - NDA 020226
4 linked pagesOpen original ·
fda-provayblue-labelMitochondrial respiration as a target for neuroprotection and cognitive enhancement
Mitochondrial respiration as a target for neuroprotection and cognitive enhancement
4 linked pagesOpen original ·
pubmed-methylene-blue-mitochondrial-2014Therapeutic benefits of methylene blue on cognitive impairment during chronic cerebral hypoperfusion
Therapeutic benefits of methylene blue on cognitive impairment during chronic cerebral hypoperfusion
3 linked pagesOpen original ·
pubmed-methylene-blue-cognitive-2014Methylene blue - Wikipedia
Methylene blue - Wikipedia
1 linked pageOpen original ·
wikipedia-methylene-blueRelated compounds
Metformin
Metformin is an FDA-approved medicine for type 2 diabetes. Longevity interest comes from biological mechanisms, observat...
Evidence review5-Amino-1MQ
5-Amino-1MQ is a small-molecule NNMT inhibitor with published efficacy findings limited to cell and rodent studies. No e...
Regulatory watchAOD-9604
AOD-9604 is a synthetic fragment of human growth hormone developed as a weight-loss candidate. Its Phase 2 obesity progr...
Regulatory watchArgireline (acetyl hexapeptide-8)
Small studies have reported modest wrinkle changes with some Argireline formulations, but results are inconsistent and o...
Evidence reviewStay informed